Attention Deficit / Hyperactivity Disorder (ADHD).
Rubicrono is indicated as part of a comprehensive treatment program for Attention Deficit Hyperactivity Disorder (ADHD) in children from 6 years of age when other measures, by themselves, have proven to be insufficient. The treatment should be under the supervision of a specialist in behavioral disorders in children. The diagnosis must be made according to the current DSM criteria or the guidelines of the CIE and must be based on the complete history and evaluation of the patient. The diagnosis can not be established only with the presence of one or more symptoms.
In adolescents whose symptoms persist until adulthood and who have shown a clear benefit with the treatment, it may be appropriate to continue with it in adulthood. However, it is not appropriate to start treatment with Rubicrono in adults.
Download sheetProlonged-release tablet:
Rubicrono® 18 mg prolonged-release tablet EFG. Yelow tablet
Rubicrono® 27 mg.Gray tablet
Rubicrono® 36 mg. White tablet
Rubicrono® 54 mg. Reddish brown tablet
Treatment should be initiated under the supervision of a specialist in behavioral disorders in children and / or adolescents.
Screening Pre-treatment
Before prescribing, it is necessary to perform a baseline assessment of the patient’s cardiovascular status, including blood pressure and heart rate. Concomitant medication, past and present comorbid and psychiatric symptoms or disorders, a family history of sudden cardiac / unexplained death, and a detailed record of height and weight before treatment on a growth chart should be documented in the full story.
The growth and the psychiatric and cardiovascular states must be continuously controlled and patients must be controlled for the risk of misuse, abuse and trafficking of methylphenidate.
Rubicrono should be swallowed whole with the help of liquids and should not be chewed, split or crushed
It can be administered with or without food and is administered once a day in the morning.
RUBICRONO® is presented in bottles with child-resistant closure and silica gel desiccant inserted in the lid, containing 30 prolonged-release tablets.
